Bicalutamide
Active ingredient: Bicalutamide
In short: Bicalutamide tablets 50 mg daily is indicatedfor use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2metastatic carcinoma of the prostate. Bicalutamide tablets 150 mg daily is not approvedfor use alone or with other treatments .
What is Bicalutamide used for?
Bicalutamide tablets 50 mg daily is indicatedfor use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D
2metastatic carcinoma of the prostate.
Bicalutamide tablets 150 mg daily is not approvedfor use alone or with other treatments
.
Bicalutamide dosage
The recommended dose for bicalutamide therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog. If a dose of bicalutamide tablets is missed, take the next dose at the scheduled time. Do not take the missed dose and do not double the next dose.
No dosage adjustment is necessary for patients with renal impairment
.
No dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary
.
How to take Bicalutamide — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Dose and Schedule:Inform patients that therapy with bicalutamide tablets and the LHRH analog should be started at the same time and that they should not interrupt or stop taking these medications without consulting their healthcare provider
.
Hepatitis:Inform patients that bicalutamide tablets can cause hepatitis, which may result in hepatic failure and death. Advise patients that liver function tests should be monitored regularly during treatment and to report signs and symptoms of hepatitis
.
Hemorrhage with Concomitant Use of Coumarin Anticoagulant:Inform patients that serious bleeding has occurred with reported increased anticoagulant effects while taking bicalutamide tablets. Advise patients to notify their healthcare provider of any bleeding or spontaneous bruising while on bicalutamide tablets and taking anticoagulants
.
Glucose Tolerance:Inform patients that diabetes or loss of glycemic control in patients with pre-existing diabetes has been reported during treatment with LHRH agonists. …
Warnings & precautions
Do not take this medicine if: Bicalutamide tablets are contraindicated in:
Hypersensitivity
Bicalutamide tablets are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. Hypersensitivity reactions including angioneurotic edema and urticaria have been reported.
Women
Bicalutamide tablets have no indication for women, and should not be used in this population.
Pregnancy
Bicalutamide tablets can cause fetal harm when administered to a pregnant woman
.
Cases of death or hospitalization due to severe liver injury (hepatic failure) have been reported postmarketing in association with the use of bicalutamide tablets. Hepatotoxicity in these reports generally occurred within the first three to four months of treatment. Hepatitis or marked increases in liver enzymes leading to drug discontinuation occurred in approximately 1% of bicalutamide tablet patients in controlled clinical trials.
Serum transaminase levels should be measured prior to starting treatment with bicalutamide tablets, at regular intervals for the first four months of treatment, and periodically thereafter. If clinical symptoms or signs suggestive of liver dysfunction occur (e.g., nausea, vomiting, abdominal pain, fatigue, anorexia, “flu-like” symptoms, dark urine, jaundice, or right upper quadrant tenderness), the serum transaminases, in particular the serum ALT, should be measured immediately. If at any time a patient has jaundice, or their ALT rises above two times the upper limit of normal, bicalutamide tablets should be immediately discontinued with close follow-up of liver function. …
Bicalutamide side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In patients with advanced prostate cancer treated with bicalutamide in combination with an LHRH analog, the most frequent adverse reaction was hot flashes (53%).
In the multi-center, double-blind, controlled clinical trial comparing bicalutamide 50 mg once daily with flutamide 250 mg three times a day, each in combination with an LHRH analog, the following adverse reactions with an incidence of 5% or greater, regardless of causality, have been reported.
Body System Adverse Reaction | Treatment Group Number of Patients (%)
Bicalutamide Plus LHRH Analog (n=401) | Flutamide Plus LHRH Analog (n=407)
Body as a Whole
Pain (General) | 142 (35) | 127 (31)
Back Pain | 102 (25) | 105 (26)
Asthenia | 89 (22) | 87 (21)
Pelvic Pain | 85 (21) | 70 (17)
Infection | 71 (18) | 57 (14)
Abdominal Pain | 46 (11) | 46 (11)
Chest Pain | 34 (8) | 34 (8)
Headache | 29 (7) | 27 (7)
Flu Syndrome | 28 (7) | 30 (7)
Cardiovascular
Hot Flashes | 211 (53) | 217 (53)
Hypertension | 34 (8) | 29 (7)
Digestive
Constipation | 87 (22) | 69 (17)
Nausea | 62 (15) | 58 (14)
Diarrhea | 49 (12) | 107 (26)
Increased Liver Enzyme Test | 30 (7) | 46 (11)
Dyspepsia | 30 (7) | 23 (6)
Flatulence | 26 (6) | 22 (5)
Anorexia | 25 (6) | 29 (7)
Vomiting | 24 (6) | 32 …
Drug interactions
Clinical studies have not shown any drug interactions between bicalutamide and LHRH analogs (goserelin or leuprolide). There is no evidence that bicalutamide induces hepatic enzymes.
In vitrostudies have shown that R-bicalutamide is an inhibitor of CYP 3A4 with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity. Clinical studies have shown that with co-administration of bicalutamide, mean midazolam (a CYP 3A4 substrate) levels may be increased 1.5-fold (for C
max) and 1.9-fold (for AUC). Hence, caution should be exercised when bicalutamide is co-administered with CYP 3A4 substrates.
In vitroprotein binding studies have shown that bicalutamide can displace coumarin anticoagulants from binding sites. PT/INR should be closely monitored in patients concomitantly receiving coumarin anticoagulants and bicalutamide. Adjustment of the anticoagulant dose may be necessary
.
About this medicine
Bicalutamide Tablets USP contain 50 mg of bicalutamide USP, a non-steroidal androgen receptor inhibitor with no other known endocrine activity. The chemical name is propanamide, N [4 cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,(+-). The structural and empirical formulas are:
Bicalutamide has a molecular weight of 430.37. The pKa is approximately 12. Bicalutamide is a fine white to off-white powder which is practically insoluble in water at 37°C (5 mg per 1000 mL), slightly soluble in chloroform and absolute ethanol, sparingly soluble in methanol, and soluble in acetone and tetrahydrofuran.
Bicalutamide is a racemate with its antiandrogenic activity being almost exclusively exhibited by the R-enantiomer of bicalutamide; the S-enantiomer is essentially inactive.
The inactive ingredients of Bicalutamide Tablets USP are lactose, magnesium stearate, hypromellose, polyethylene glycol, polyvidone, sodium starch glycollate, and titanium dioxide.
How it works: Bicalutamide is a non-steroidal androgen receptor inhibitor. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 26e30155-a50b-df14-e063-6394a90a9be4. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate